Locations:
Search IconSearch

Tag: HER2-positive breast cancer

Dr. Jame Abraham
October 20, 2025/Cancer/News & Insight

Trastuzumab Deruxtecan Improves Invasive Disease-Free Survival of Early-Stage HER+ Breast Cancer by 53%

International study supports change in clinical care in post-neoadjuvant setting

650×450-Breast-Cancer
November 13, 2020/Cancer/Tumor Oncology

Global Trial Seeks New Gold Standard Treatment for HER2+ Early Breast Cancer in Post-Neoadjuvant Setting

New drug among the most potent antibody-drug conjugates in development

Breast-cancer_650x450
December 5, 2018/Cancer/News & Insight

Adjuvant T-DM1 Superior to Trastuzumab in Patients with HER2+ Early Breast Cancer

Increased invasive disease-free survival, disease-free survival and overall survival

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

BackPage 1 of 1Next

Advertisement

Ad